MABTHERA 500 MG PERF FL 50 ML
(Rituximab) - Maladie rare sans désignation orpheline
* Non-Hodgkin’s lymphoma (NHL)
- Treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy.
- As maintenance therapy, the treatment of follicular lymphoma patients responding to induction therapy.
- In monotherapy, treatment of patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.
- Treatment of patients with CD20 positive diffuse large B cell non- Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
* In combination with chemotherapy, treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including MabThera or patients refractory to previous MabThera plus chemotherapy.
* Granulomatosis with polyangiitis and Microscopic polyangiitis in combination with glucocorticoids, is indicated for the induction of remission in adult patients with severe, active Granulomatosis with polyangiitis (Wegener’s) (GPA) and Microscopic polyangiitis (MPA).